Clinical Evidence of Mesenchymal Stromal Cells for Cerebral Palsy: Scoping Review with Meta-Analysis of Efficacy in Gross Motor Outcomes DOI Creative Commons
Madison C. B. Paton, Alexandra R. Griffin,

Remy Blatch-Williams

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(10), P. 700 - 700

Published: May 12, 2025

Mesenchymal stromal cells (MSCs) have been under clinical investigation for the treatment of cerebral palsy (CP) over a decade. However, field has limited by study heterogeneity and variable reports efficacy. We conducted scoping review published registered MSC CP, with meta-analysis Gross Motor Function Measure (GMFM) outcomes to summarize research provide future recommendations. Thirty 10 trials were identified, including 1292 people CP receiving MSCs. Most received ≥2 doses (72%) umbilical cord tissue MSCs (75%), intrathecally (40%) or intravenously (38%), 31% treated via compassionate/Expanded access. was safe meta-analyses demonstrated that conferred significant improvements in GMFM at 3 − (1.05 (0.19–1.92), p = 0.02), 6 (0.97 (0.30–1.64), 0.005) 12 months (0.99 (0.30–1.67), post-treatment. Whilst are improve large effect sizes, participant variability continues confound data interpretation limits subgroup analyses. With no Phase high rates compassionate access, would benefit from well-designed unified outcomes. Additionally, sharing enable Individual Participant Data Meta-Analysis support determination optimal source, route dose progress towards regulatory approval.

Language: Английский

Cord Blood Treatment for Children With Cerebral Palsy DOI
Peter Rosenbaum, Robert J. Palisano

PEDIATRICS, Journal Year: 2025, Volume and Issue: unknown

Published: April 11, 2025

Language: Английский

Citations

0
Clinical Evidence of Mesenchymal Stromal Cells for Cerebral Palsy: Scoping Review with Meta-Analysis of Efficacy in Gross Motor Outcomes DOI Creative Commons
Madison C. B. Paton, Alexandra R. Griffin,

Remy Blatch-Williams

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(10), P. 700 - 700

Published: May 12, 2025

Mesenchymal stromal cells (MSCs) have been under clinical investigation for the treatment of cerebral palsy (CP) over a decade. However, field has limited by study heterogeneity and variable reports efficacy. We conducted scoping review published registered MSC CP, with meta-analysis Gross Motor Function Measure (GMFM) outcomes to summarize research provide future recommendations. Thirty 10 trials were identified, including 1292 people CP receiving MSCs. Most received ≥2 doses (72%) umbilical cord tissue MSCs (75%), intrathecally (40%) or intravenously (38%), 31% treated via compassionate/Expanded access. was safe meta-analyses demonstrated that conferred significant improvements in GMFM at 3 − (1.05 (0.19–1.92), p = 0.02), 6 (0.97 (0.30–1.64), 0.005) 12 months (0.99 (0.30–1.67), post-treatment. Whilst are improve large effect sizes, participant variability continues confound data interpretation limits subgroup analyses. With no Phase high rates compassionate access, would benefit from well-designed unified outcomes. Additionally, sharing enable Individual Participant Data Meta-Analysis support determination optimal source, route dose progress towards regulatory approval.

Language: Английский

Citations

0